FDA Releases Draft Guidance for Industry on IND Meetings for Human Drugs and Biologics

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommendations for formal meetings between pharmaceutical companies and the FDA's Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) regarding chemistry, manufacturing, and controls information for human drugs and biologics.